|
1
|
Culakova E, Thota R, Poniewierski MS,
Kuderer NM, Wogu AF, Dale DC, Crawford J and Lyman GH: Patterns of
chemotherapy-associated toxicity and supportive care in US oncology
practice: A nationwide prospective cohort study. Cancer Med.
3:434–444. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Fontanella C, Bolzonello S, Lederer B and
Aprile G: Management of breast cancer patients with
chemotherapy-induced neutropenia or febrile neutropenia. Breast
Care (Basel). 9:239–245. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh
MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JA and Wingard
JR: Infectious Diseases Society of America: Clinical practice
guideline for the use of antimicrobial agents in neutropenic
patients with cancer: 2010 update by the infectious diseases
society of america. Clin Infect Dis. 52:e56–e93. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Masaoka T: Evidence-based recommendations
for antimicrobial use in febrile neutropenia in Japan: Executive
summary. Clin Infect Dis. 39(Suppl 1): S49–S52. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Takamatsu Y: A general description of the
clinical guideline for the management of febrile neutropenia. Gan
To Kagaku Ryoho. 40:697–702. 2013.(In Japanese). PubMed/NCBI
|
|
6
|
Flowers CR, Seidenfeld J, Bow EJ, Karten
C, Gleason C, Hawley DK, Kuderer NM, Langston AA, Marr KA, Rolston
KV and Ramsey SD: Antimicrobial prophylaxis and outpatient
management of fever and neutropenia in adults treated for
malignancy: American Society of Clinical Oncology clinical practice
guideline. J Clin Oncol. 31:794–810. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Baden LR, Bensinger W, Angarone M, Casper
C, Dubberke ER, Freifeld AG, Garzon R, Greene JN, Greer JP, Ito JI,
et al: Prevention and treatment of cancer-related infections. J
Natl Compr Canc Netw. 10:1412–1445. 2012.PubMed/NCBI
|
|
8
|
Klastersky J, Paesmans M, Rubenstein EB,
Boyer M, Elting L, Feld R, Gallagher J, Herrstedt J, Rapoport B,
Rolston K and Talcott J: The multinational association for
supportive care in cancer risk index: A multinational scoring
system for identifying low-risk febrile neutropenic cancer
patients. J Clin Oncol. 18:3038–3051. 2000.PubMed/NCBI
|
|
9
|
Teuffel O, Ethier MC, Alibhai SM, Beyene J
and Sung L: Outpatient management of cancer patients with febrile
neutropenia: A systematic review and meta-analysis. Ann Oncol.
22:2358–2365. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mizuno T, Katsumata N, Mukai H, Shimizu C,
Ando M and Watanabe T: The outpatient management of low-risk
febrile patients with neutropenia: Risk assessment over the
telephone. Support Care Cancer. 15:287–291. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Dulisse B, Li X, Gayle JA, Barron RL,
Ernst FR, Rothman KJ, Legg JC and Kaye JA: A retrospective study of
the clinical and economic burden during hospitalizations among
cancer patients with febrile neutropenia. J Med Econ. 16:720–735.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hendricks AM, Loggers ET and Talcott JA:
Costs of home versus inpatient treatment for fever and neutropenia:
Analysis of a multicenter randomized trial. J Clin Oncol.
29:3984–3989. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Teuffel O, Cheng S, Ethier MC, Diorio C,
Martino J, Mayo C, Wing R, Sung L and Alibhai SM: Health-related
quality of life anticipated with different management strategies
for febrile neutropenia in adult cancer patients. Support Care
Cancer. 20:2755–2764. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Charlson ME, Pomei P, Alles KL and
MacKenzie CR: A new method of classifying prognostic comorbidity in
longitudinal studies: development and validation. J Chronic Dis.
40:373–383. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chamilos G, Bamias A, Efstathiou E, Zorzou
PM, Kastritis E, Kostis E, Papadimitriou C and Dimopoulos MA:
Outpatient treatment of low-risk neutropenic fever in cancer
patients using oral moxifloxacin. Cancer. 103:2629–2635. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sebban C, Dussart S, Fuhrmann C,
Ghesquieres H, Rodrigues I, Geoffrois L, Devaux Y, Lancry L,
Chvetzoff G, Bachelot T, et al: Oral moxifloxacin or intravenous
ceftriaxone for the treatment of low-risk neutropenic fever in
cancer patients suitable for early hospital discharge. Support Care
Cancer. 16:1017–1023. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Rolston KV, Frisbee-Hume SE, Patel S,
Manzullo EF and Benjamin RS: Oral moxifloxacin for outpatient
treatment of low-risk, febrile neutropenic patients. Support Care
Cancer. 18:89–94. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lyman GH, Dale DC and Crawford J:
Incidence and predictors of low dose-intensity in adjuvant breast
cancer chemotherapy: A nationwide study of community practices. J
Clin Oncol. 21:4524–4531. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Griffin DA, Penprase B and Klamerus JF:
Relative dose intensity-improving treatment and outcomes in
early-stage breast cancer: A retrospective study. Oncol Nurs Forum.
39:E459–E467. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chong Y, Shimoda S, Yakushiji H, Ito Y,
Aoki T, Miyamoto T, Kamimura T, Shimono N and Akashi K: Clinical
impact of fluoroquinolone-resistant Escherichia coli in the fecal
flora of hematological patients with neutropenia and levofloxacin
prophylaxis. PLoS One. 9:e852102014. View Article : Google Scholar : PubMed/NCBI
|
